Marimed (MRMD) EV to EBITDA (2012 - 2026)

Marimed (MRMD) has reported EV to EBITDA for 15 consecutive years, with 42.44 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 121.12% year-over-year to 42.44 in Q2 2026; TTM through Jun 2026 was 7.44, a 99.35% increase from a year earlier, with the FY2025 full-year figure at 8.86, down 162.89% from the prior year.
• EV to EBITDA was 42.44 for Q2 2026 at Marimed, down from 144.76 in the prior quarter.
• Over five years, EV to EBITDA peaked at 144.76 in Q1 2026 and troughed at 28.57 in Q1 2025.
• A 5-year average of 32.36 and a median of 34.66 in 2022 frame the typical range for EV to EBITDA.
• Across the five-year window, EV to EBITDA sank 171.56% in 2025 and soared 606.6% in 2026, its largest moves.
• Over 5 years, EV to EBITDA stood at 36.12 in 2022, then climbed by 1.81% to 36.77 in 2023, then tumbled by 168.07% to 25.03 in 2024, then surged by 77.95% to 5.52 in 2025, then surged by 868.86% to 42.44 in 2026.
• The last three EV to EBITDA figures came in at 42.44 (Q2 2026), 144.76 (Q1 2026), and 5.52 (Q4 2025), per Business Quant data.